[Recent advances in pathogenesis and therapy of multiple sclerosis].
暂无分享,去创建一个
[1] H. Maruyama,et al. Functional , 2020, Congress of Neurological Surgeons Essent.
[2] C. Stadelmann,et al. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis , 2004, Cell Death and Differentiation.
[3] S. Morrow,et al. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis , 2004, Neurology.
[4] T. Henze,et al. Symptomatische Therapie der Multiplen Sklerose , 2004, Der Nervenarzt.
[5] T. Waldmann,et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[6] C. Baecher-Allan,et al. T Cell Ig- and Mucin-Domain-Containing Molecule-3 (TIM-3) and TIM-1 Molecules Are Differentially Expressed on Human Th1 and Th2 Cells and in Cerebrospinal Fluid-Derived Mononuclear Cells in Multiple Sclerosis1 , 2004, The Journal of Immunology.
[7] H. Hartung,et al. Are statins a treatment option for multiple sclerosis? , 2004, The Lancet Neurology.
[8] V. Durkalski,et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis , 2004, The Lancet.
[9] D. Bechtold,et al. Axonal protection using flecainide in experimental autoimmune encephalomyelitis , 2004, Annals of neurology.
[10] R. Ravid,et al. Expression of CCR7 in multiple sclerosis: Implications for CNS immunity , 2004, Annals of neurology.
[11] Clare Baecher-Allan,et al. Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis , 2004, The Journal of experimental medicine.
[12] F. Zipp,et al. Direct Impact of T Cells on Neurons Revealed by Two-Photon Microscopy in Living Brain Tissue , 2004, The Journal of Neuroscience.
[13] K. Rajewsky,et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[14] P. Nibbering,et al. Monomethylfumarate affects polarization of monocyte‐derived dendritic cells resulting in down‐regulated Th1 lymphocyte responses , 2004, European journal of immunology.
[15] G. Freeman,et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance , 2003, Nature Immunology.
[16] P. Sørensen,et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis , 2003, The Lancet.
[17] Stephen G Waxman,et al. Temporal Course of Upregulation of Nav1.8 in Purkinje Neurons Parallels the Progression of Clinical Deficit in Experimental Allergic Encephalomyelitis , 2003, Journal of neuropathology and experimental neurology.
[18] B D Trapp,et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration , 2003, Multiple sclerosis.
[19] R. Gold,et al. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. , 2003, Brain : a journal of neurology.
[20] Stephen G Waxman,et al. Abnormal sodium channel distribution in optic nerve axons in a model of inflammatory demyelination. , 2003, Brain : a journal of neurology.
[21] P. Tak,et al. Gene therapy in nonhuman primate models of human autoimmune disease , 2003, Gene Therapy.
[22] L. Munari,et al. Interferons in relapsing remitting multiple sclerosis : a systematic review , 2022 .
[23] V. Rivera,et al. Cross‐reactivity with myelin basic protein and human herpesvirus‐6 in multiple sclerosis , 2003, Annals of neurology.
[24] K. Jellinger,et al. Preferential Loss of Myelin‐Associated Glycoprotein Reflects Hypoxia‐Like White Matter Damage in Stroke and Inflammatory Brain Diseases , 2003, Journal of neuropathology and experimental neurology.
[25] H. Hartung,et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial , 2002, The Lancet.
[26] P M Matthews,et al. Functional brain reorganization for hand movement in patients with multiple sclerosis: defining distinct effects of injury and disability. , 2002, Brain : a journal of neurology.
[27] K. Selmaj,et al. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment , 2002, European journal of neurology.
[28] D. Goodkin,et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis , 2002, Multiple sclerosis.
[29] Wolfgang Brück,et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. , 2002, Brain : a journal of neurology.
[30] Hans Lassmann,et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. , 2002, Brain : a journal of neurology.
[31] M. Elices. BX-471 Berlex. , 2002, Current opinion in investigational drugs.
[32] H. Lassmann,et al. CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation , 2002, Nature Medicine.
[33] W. Voelker,et al. Myocardial function in patients with multiple sclerosis treated with low-dose mitoxantrone. , 2002, The American journal of cardiology.
[34] A. Ghezzi,et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) , 2002, The Lancet.
[35] R. Gold,et al. Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis , 2002, Acta Neuropathologica.
[36] B. Weinshenker,et al. Plasma exchange for severe attacks of CNS demyelination: Predictors of response , 2002, Neurology.
[37] S. Krauss,et al. Signaling takes a breath--new quantitative perspectives on bioenergetics and signal transduction. , 2001, Immunity.
[38] B. Trapp,et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.
[39] Lawrence Steinman,et al. Multiple sclerosis: a two-stage disease , 2001, Nature Immunology.
[40] M. Bahr,et al. Acute Neuronal Apoptosis in a Rat Model of Multiple Sclerosis , 2001, The Journal of Neuroscience.
[41] T. Derfuss,et al. Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response. , 2001, Brain : a journal of neurology.
[42] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[43] C. Lucchinetti,et al. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions , 2001, Annals of neurology.
[44] H. Lassmann,et al. Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. , 2001, Brain : a journal of neurology.
[45] H. Lassmann,et al. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. , 2001, Immunity.
[46] R. Horuk,et al. CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. , 2001, Immunology letters.
[47] W. Brück,et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. , 2000, Brain : a journal of neurology.
[48] L. Boon,et al. A new primate model for multiple sclerosis in the common marmoset. , 2000, Immunology today.
[49] R. Hohlfeld,et al. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. , 2000, Brain : a journal of neurology.
[50] B. Scheithauer,et al. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. , 1999, Brain : a journal of neurology.
[51] D. MacManus,et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. , 1999, Neurology.
[52] Hans Lassmann,et al. Activated Human T Cells, B Cells, and Monocytes Produce Brain-derived Neurotrophic Factor In Vitro and in Inflammatory Brain Lesions: A Neuroprotective Role of Inflammation? , 1999, The Journal of experimental medicine.
[53] H. Weiner,et al. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin‐4 production and associated eosinophilia , 1997, Annals of neurology.
[54] B. Kieseier,et al. Targets for the therapeutic action of interferon‐β in multiple sclerosis , 1996, Annals of neurology.
[55] Moses Rodriguez,et al. Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis , 1996, Brain pathology.
[56] A. Thompson,et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. , 1996, Brain : a journal of neurology.
[57] A. Thompson,et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. , 1995, Brain : a journal of neurology.
[58] R. Holmdahl,et al. Identification of murine loci associated with susceptibility to chronic experimental autoimmune encephalomyelitis , 1995, Nature Genetics.
[59] K. Jellinger,et al. Patterns of oligodendroglia pathology in multiple sclerosis. , 1994, Brain : a journal of neurology.
[60] H. Hartung,et al. [Cyclophosphamide in therapy of chronic progressive multiple sclerosis. Critical analysis of current studies]. , 1994, Der Nervenarzt.
[61] H. Webster,et al. Concentric sclerosis (Baló): Morphometric and in situ hybridization study of lesions in six patients , 1994, Annals of neurology.
[62] T. Mak,et al. Less Mortality but More Relapses in Experimental Allergic Encephalomyelitis in CD8-/- Mice , 1992, Science.
[63] R. Hughes,et al. Overview of azathioprine treatment in multiple sclerosis , 1991, The Lancet.
[64] L. Kappos,et al. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[65] H. Weiner,et al. T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosis , 1990, Nature.
[66] W Fierz,et al. Cyclosporine versus azathioprine in the long‐term treatment of multiple sclerosis—results of the german multicenter study , 1988, Annals of neurology.
[67] C. Spina. Azathioprine as an Immune Modulating Drug: Clinical Applications , 1984, Clinics in Immunology and Allergy.
[68] T. Rivers,et al. OBSERVATIONS ON ATTEMPTS TO PRODUCE ACUTE DISSEMINATED ENCEPHALOMYELITIS IN MONKEYS , 1933, The Journal of experimental medicine.
[69] E. Shevach. Regulatory T cells. Introduction. , 2004, Seminars in Immunology.
[70] 高橋 和也. Natural killer type 2 bias in remission of multiple sclerosis , 2003 .
[71] M. Neurath,et al. CD 28-dependent Rac 1 activation is the molecular target of azathioprine in primary human CD 4 + T lymphocytes , 2003 .
[72] Hompson,et al. A LONGITUDINAL STUDY OF ABNORMALITIES ON MRI AND DISABILITY FROM MULTIPLE SCLEROSIS , 2002 .
[73] R. Hohlfeld,et al. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. , 2002, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
[74] E. Byrne. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. , 2002, Neurology.
[75] N. Richert. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". , 2002, Neurology.
[76] P. Rieckmann,et al. Managing the adverse effects of interferon-beta therapy in multiple sclerosis. , 2000, Drug safety.
[77] ichard,et al. AXONAL TRANSECTION IN THE LESIONS OF MULTIPLE SCLEROSIS , 1998 .
[78] I. Cohen,et al. The rapid isolation of clonable antigen‐specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis , 1981, European journal of immunology.